{"transactions":[{"id":4436,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":100485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":100485},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4435,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":502423,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":100485},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4434,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":208974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2023-05-12","expiration_date":"2033-05-11","underlying":"Common Stock","underlying_shares":208974},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4433,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":208974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":393934,"derivative":{"exercise_price":0.053,"exercise_date":"2023-05-12","expiration_date":"2033-05-11","underlying":"Common Stock","underlying_shares":208974},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4432,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":90529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2022-10-05","expiration_date":"2032-10-04","underlying":"Common Stock","underlying_shares":90529},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4431,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":512379,"derivative":{"exercise_price":0.16,"exercise_date":"2022-10-05","expiration_date":"2032-10-04","underlying":"Common Stock","underlying_shares":90529},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4430,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":65620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2022-04-12","expiration_date":"2032-04-11","underlying":"Common Stock","underlying_shares":65620},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4429,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":537288,"derivative":{"exercise_price":0.16,"exercise_date":"2022-04-12","expiration_date":"2032-04-11","underlying":"Common Stock","underlying_shares":65620},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4428,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2021-05-17","expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4427,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":572908,"derivative":{"exercise_price":0.16,"exercise_date":"2021-05-17","expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4426,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2020-04-01","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4425,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":592908,"derivative":{"exercise_price":0.16,"exercise_date":"2020-04-01","expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4424,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":59530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2018-06-01","expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":59530},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4423,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":543378,"derivative":{"exercise_price":0.16,"exercise_date":"2018-06-01","expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":59530},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4422,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":37770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":602908,"derivative":{"exercise_price":0.032,"exercise_date":"2018-01-08","expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":37770},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}},{"id":4421,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10059,"kind":"person","name":"Teyssedou Lenaic Nathanael","position":1,"cik":"0002123881","reported_name":"Teyssedou Lenaic Nathanael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL ACCOUNTING OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:11:06.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":565138,"derivative":{"exercise_price":0.16,"exercise_date":"2018-01-08","expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":37770},"source":{"system":"sec-edgar","filing":"0001104659-26-105509","document":"tm2624769-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2123881/000110465926105509/tm2624769-5_4seq1.xml","form_type":"4"}}]}